EUCTR2014-004904-31-NL进行中（未招募）1 期
An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female, age =18 years.
- •2.Subject will have a confirmed diagnosis of RA, UC or CD.
- •3.Stable remission defined as HBI=4, SCCAI<3, DAS 28<3.2 at screening.
- •4.Stable and continuous treatment with Remicade during the last 30 weeks, and no foreseen dose adjustment for the coming 2 months for infliximab.
- •5.Stable concomitant treatment; if concomitant drugs than stable for 4 months and no foreseen changes in drugs.
- •For RA: stable and continuous treatment with MTX.
- •6.Non-pregnant, non-nursing female.
- •7.Subject capable of understanding and signing an informed consent form.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 59
排除标准
- •1.Subjects with evidence of the following major co-morbidities such as: severe diabetic mellitus, tuberculosis (TB), severe infections, uncontrollable hypertension, severe cardiovascular disease (New York Heart Association [NYHA] class 3 or 4) and/or severe respiratory diseases.
- •2.Any other condition/disease, which in the opinion of the investigator makes the subject ineligible for the study.
- •3.Any clinically relevant hypersensitivity to (anaphylaxis or infusion related reactions) infliximab or to other murine proteins
- •4.Change of major co-medication during the last 4 months prior to screening and foreseen dose adjustment during the next 2 months:
- •RA: Initiation of systemic corticosteroids or synthetic DMARDs or other medication, which according to the investigator would interfere with the stability of the disease.
- •UC and CD: Initiation of systemic corticosteroids or an immunosuppressant or other medication, which according to the investigator would interfere with the stability of the disease.
- •5.Change in treatment with Remicade during the last 30 weeks due to disease related factors, not including dose/frequency adjustments due to serum infliximab concentration measurements.
- •6.Simultaneous treatment with another biological or a not registered NCE.
- •7.Psychiatric or mental disorders, alcohol abuse or other substance abuse (and/or history of opioid abuse), language barriers or other factors which makes adherence to the study protocol impossible.
- •8.Inadequate birth control, pregnancy, and/or breastfeeding.
研究者
相似试验
进行中（未招募）
1 期
A clinical study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.EUCTR2014-004904-31-BEMundipharma Pharmaceuticals B.V.156
已完成
4 期
An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima* (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn*s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.Reumatoid Arthritis/RheumatismCrohn's Disease/Inflammatory Bowel Disease (IBD)Colitis Ulcerosa/IBD1001796910003816NL-OMON43846Mundipharma129
进行中（未招募）
1 期
ong-term hepatitis A and B antibody persistence in healthy adult subjects, primed 16 to 20 years earlier with GSK Biologicals’ combined hepatitis A and B vaccine, Twinrix® (SB208127) in study HAB-084 (208127/084).Healthy volunteers (Vaccination against hepatitis A and hepatitis B in healthy adults)MedDRA version: 16.1Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-004586-13-CZGlaxoSmithKline Biologicals s.a.180
已完成
不适用
Persistence of antibodies six years after priming immunisation with Meningococcal C conjugate vaccine and response to the Hib-MenC (Menitorix®) vaccine in healthy childreMeningococcal C and Haemophilus influenzae type B diseasesInfections and InfestationsISRCTN72858898niversity of Oxford (UK)250
进行中（未招募）
不适用
Evaluation of the long-term persistence of hepatitis A antibodies in healthy adults who were vaccinated 21-25 years earlier with GlaxoSmithKline (GSK) Biologicals’ hepatitis A vaccine, Havrix®.Healthy volunteers (Vaccination against hepatitis A in healthy adults)MedDRA version: 16.1Level: LLTClassification code 10052551Term: Hepatitis A virusSystem Organ Class: 100000004848EUCTR2013-001918-15-BEGlaxoSmithKline Biologicals